217 related articles for article (PubMed ID: 36457080)
1. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C; Nachury M; Bourreille A; Roblin X; Peyrin-Biroulet L; Viennot S; Flamant M; Laharie D; Caron B; Dewitte M; Siproudhis L; Fumery M; Bouguen G
BMC Gastroenterol; 2022 Dec; 22(1):498. PubMed ID: 36457080
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
[TBL] [Abstract][Full Text] [Related]
5. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
6. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Albshesh A; Bannon L; Sharar Fischler T; Truyens M; Vavricka SR; Tepes K; Pugliese D; Savarino EV; Zittan E; Drobne D; Roblin X; Bar-Gil Shitrit A; Armuzzi A; Lobaton T; Maharshak N; Yanai H; Ben-Horin S; Kopylov U
J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048587
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Biologic Therapies in Preventing Penetrating Complications in Patients With Crohn's Disease.
McCurdy JD; Stwalley D; Olsen MA; Deepak P
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):377-385.e5. PubMed ID: 37673348
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.
Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Inflamm Bowel Dis; 2022 Feb; 28(2):218-225. PubMed ID: 33847351
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
[TBL] [Abstract][Full Text] [Related]
13. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
Louis E; Litkiewicz M; Agboton C; Armuzzi A
United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
[TBL] [Abstract][Full Text] [Related]
15. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
[TBL] [Abstract][Full Text] [Related]
16. Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
Abd El Aziz MA; Abdalla S; Calini G; Saeed H; Stocchi L; Merchea A; Colibaseanu DT; Shawki S; Larson DW
J Crohns Colitis; 2022 Aug; 16(7):1079-1088. PubMed ID: 35045164
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease.
Shiga H; Tarasawa K; Moroi R; Makuuchi M; Takahashi T; Shimoyama Y; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Nov; 37(11):2105-2112. PubMed ID: 36059265
[TBL] [Abstract][Full Text] [Related]
18. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
[TBL] [Abstract][Full Text] [Related]
19. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]